MARKET

NBP

NBP

NovaBridge Biosciences
NASDAQ
3.340
-0.080
-2.34%
Opening 13:39 02/11 EST
OPEN
3.410
PREV CLOSE
3.420
HIGH
3.450
LOW
3.300
VOLUME
178.19K
TURNOVER
--
52 WEEK HIGH
6.79
52 WEEK LOW
0.5950
MARKET CAP
385.07M
P/E (TTM)
-11.8146
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NBP last week (0202-0206)?
Weekly Report · 2d ago
Amazon downgraded, Roblox upgraded: Wall Street’s top analyst calls
TipRanks · 5d ago
Amazon To $300? Here Are 10 Top Analyst Forecasts For Friday
Benzinga · 5d ago
NovaBridge Biosciences Unveils February 2026 Investor Presentation Highlighting Global Hub-and-Spoke Biotech Strategy
TipRanks · 5d ago
NovaBridge Biosciences Price Target Raised to $9.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 5d ago
NovaBridge Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 5d ago
HC Wainwright & Co. Maintains Buy on NovaBridge Biosciences, Raises Price Target to $9
Benzinga · 5d ago
Reaffirming Buy on NovaBridge Biosciences: Differentiated Givastomig Profile, Expanded Patient Reach, and Strengthened Long-Term Value Proposition
TipRanks · 5d ago
More
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.

Webull offers NovaBridge Biosciences stock information, including NASDAQ: NBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NBP stock methods without spending real money on the virtual paper trading platform.